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Summary
A low molecular weight heparin (enoxaparin, mean molecular
weight - 4,400) was separated by gel chromatography into eight
different fractions with a narrow distribution around the following
mean molecular weights : L,800, 2,400, 2,900, 4,200, 6,200, 8,600,
9,800 and 11,000. We compared the influence of enoxaparin on
the generation of thrombin in plasma to that of the eight fractions.
We determined: a) the 7" of mateial with high affinity to
antithrombin III (HAM) and the % of HAM above the critical
chainlength necessary to allow for thrombin inhibition (ACLM),
b) the specific catalytic activity on the decay of endogenous
thrombin, and c) the inhibition of over-all thrombin formation in
the extrinsic and the intrinsic pathway. From b and c we
calculated the inhibition of prothrombin conversion in these
pathways.
We found that a) there is a gradual decrease of the HAM
fraction with decreasing molecular weight; b) the specific catalytic
activity for the inactivation of thrombin does not vary significantly
between the fractions when expressed in terms of ACLM; c) the
potency to inhibit prothrombin conversion does not vary signifi-
cantly between the fractions when expressed in terms of HAM.
lntroduction
Prevention of the appearance of free thrombin at a site where
the blood coagulation mechanism is triggered is putatively the
main mechanism by which antithrombotic pharmaceuticals exert
their action (1). Heparins act by enhancing the inactivation of
activated clotting factors by AT III. Heparin cofactor II is
stimulated only at concentrations that are not usually attained in
clinical practise. Consequently only those molecules that bind to
AT III, i. e. the high affinity material (HAM), is capable to affect
blood coagulation in a patient. Heparins loose their capacity to
catalyse the AI III dependent inhibition of thrombin with
decreasing molecular weight (2-6). Barrowcliffe et al. (5), and
Thomas et al. (6) have shown that heparin fragments with a
chainlength of 10-18 monosaccharide units have a high anti-factor
Xa activity, and that a length of 20-22 saccharides is minimally
required for an antithrombin activity. Lane and coworkers (4)
studied heparins of 8 to > 18 monosaccharides and concluded
that 18 units is the smallest chainlength that will allow to
potentiate the inactivation of thrombin, shorter species catalysing
factor Xa inactivation only. So all the HAM in a heparin has anti-
factor Xa acitivity, whereas antithrombin activity is expressed in
HAM above the critical chainlength of l-8 monosaccharides
(ACLM) only. It therefore appeared logical that low molecular
weight heparins should owe their antithrombotic action at least in
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part to their anti-factor Xa activity. From there it was a small step
to surmise that LMWHs with a high ratio of anti-factor Xa- to
antithrombin activity could make better antithrombotics than
conventional. unfractionated heparins (7).
The inhibitory actions of a heparin measured on isolated
factors do not, however, necessarily directly reflect its activities in
the complex medium of plasma (8-11). In order to study the
effects of heparins under the conditions prevailing in clotting
plasma, a method has been developed in our laboratory that
allows the calculation of the conversion rate of prothrombin,
independent of the simultaneous breakdown of the thrombin
generated (8). BV this approach it could be shown that:
1. Unfractionated heparin (UFH) acts mainly by enhancing
thrombin breakdown, its effect on the inhibition of prothrom-
binase in the extrinsic pathway is of minor i.mportance (12).
2. The synthetic pentasaccharide (PS) that represents the AT III-
binding site of heparin (13), and that does not catalyse direct
inhibition of thrombin (14), unlike UFH does inhibit pro-
thrombinase via its action on inhibition of free factor Xa (15).
3. Most low molecular weight heparins (LMWHs) act rather like
standard heparin, in that they have a minor influence on the
prothrombinase activity in plasma, even though the anti-factor
Xalantithrombin ratio is reported to be high (16).
One of the LMWH preparations that we studied, PK 10169 or
enoxaparin, caused a relatively high inhibition of prothrombin
conversion. This has previously been explained as being caused by
a high proportion of pentasaccharide like material (17). In this
study we want to establish what material in enoxaparin is
responsible for its over-all action on blood coagulation. To this
end we prepared from enoxaparin eight fractions with largely
different average molecular weight (MW) and a narrow MW
distribution. We studied the anti-thrombin and anti-prothrombin-
ase properties as a function of the HAM and the ACLM content
of these fractions.
Materials and Methods
Materials
Three batches of the low molecular weight heparin enoxaparin
(88.145.02; 89.009.01;89.037 01) were supplied by Rh6ne-Poulenc Rorer:
They were prepared from heparin by chemical B-elimination. Three runs
were performed with different batches of heparin. The average MW of the
three batches of enoxaparin were around 4,400, 4,500, and 4,500
respectively. Their anti-factor Xa activities (18, 19) were 115, I20 and
108.5 IU/mg. Their activity in the European pharmacopoeia method (i. e.
an activated partial thromboplastin time in sheep plasma) was 56.3, 66 and
57 lUlmg respectively
From one of these batches (88.145.02) eight fractions with narrow MW
distribution were obtained (see Methods).
The chromogenic substrate for thrombin, H.D-Phe-Pip-Arg-pNA (S-
2238), was obtained from Kabi, Sweden. Kaolin (Kaolin l6ger) was
provided by B L B. Laboratoires du Bois de Boulogne (Puteaux,
France).
Buffer A: 0.05 M Tiis-HCl, 0 1 M NaCl, 0.5 mg/ml
albumin, pH 7.35.
Buffer B: 0.05 M Tiis-HCl, 0.1 M NaCl, 0.5 mg/ml
albumin with 20 mM EDTA at pH 7.90.
Plasma
increase can subsequently be plotted as a function of the heparin
concentration (in pglml). Upon addition of increasing amounts of heparin,
the fluorescence of AT III increases proportionally with the heparin
concentration until the equivalence point has been reached The concen-
tration of the heparin fraction at the inflection point (in pglml), contains
the number of binding sites present in the AT III added, i. e. 0.5 pM It
should be noted that this determination is independent of the magnitude
of the fluorescence change, i.e. independent of possible changes of
fluorescence with the chainlength of the heparin The AT III itself has
been titrated with synthetic pentasaccharide that is assumed to contain
100% high affinity material. In this way one obtains the molar concentra-
tion of binding sites per mg of heparin Knowing the MW of the heparin
we can then calculate the percentage of high affinity molecules in the
heparin preparation. The titration was carried out on a SLM Aminco SPF-
500 C spectrofluorometer.
Rate Constants of Inactivation of Endogenous Thrombtn
Defibrinated plasma (120 pl) is mixed with bufi'er A (14 pl), and
prewarmed for 5 minutes at 37' C. Thrombin generation is started by the
addition of 30 pl of thromboplastin dilution Two minutes after the peak
activity of thrombin, 6 pl of a 10 mg/ml Soybean Tiypsin Inhibitor (SBTI)
solution (8), is added together with 10 pl of buffer that contains the
heparin to be tested. At suitable intervals after this addition 10 pl aliquots
of the incubation mixture are transferred to cuvettes containing 0.2 mM of
5-2238 in 490 pl of buffer B, to measure residual thrombin activity. After
120 s, the reaction in the cuvette is stopped by adding 300 pl of
concentrated acetic acid. The pseudo-first order rate constant of inhibition
o o o
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Fig 1 Fluorescence titration of AT III with enoxaparin. The fluores-
cence increase of 0.5 uM AT III is calculated as indicated in the methods
section. At the equivalence point the concentration of enoxaparin was
L6 pglml
human serum
human serum
Blood from ten healthy donors was collected on 0.13 M trisodium
citrate; nine parts of blood to one part of citrate solution. A first and a
second centrifugation were done at 15" C, during 15 min at 3,000 x g, and
a third centrifugation was done at 4" C, for t hour at 23,000 x g The
platelet fiee plasma thus obtained was stored at -80" C. It was checked
that the clotting factors and the antiproteases were in the normal range.
Defibrinated plasma was obtained by mixing an aliquot of plasma with
1 : 50 volume of a reptilase solution, letting a clot form for 5 min at37' C,
and keeping the clotted plasma at 4' C for 10 min The fibrin formed was
discarded by winding it on a small plastic spatula. As it was previously
shown, the concentration of factors II, VII, VIII, IX, X, XI and XII does
not change significantly by the reptilase treatment (8).
Proteins
Reptilase was obtained from Boehringer Mannheim (Mannheim,
Germany) and dissolved according to the instructions of the manufac-
turer. Soybean Tiypsin Inhibitor, (batch No. 43 F 8000) was obtained
from Sigma (St. Louis, MO). Staphylocoagulase was obtained from
Laboratoires Stago (Asnidres, France) and reconstituted according to the
instructions of the manufacturer. Human AT III was a gift of Prof. H.
Goudemand (Lille, France) It had been prepared by polyethylene glycol
precipitation of barium citrate-adsorbed plasma and affinity chromatogra-
phy on a heparin-sepharose column (20). The AT III was subsequently
freed of remaining heparin by ion exchange chromatography (21). Its
activity was assessed by titration with active site titrated factor Xa (22).
Human brain thromboplastin was prepared according to Owren and Aas
(23). Before use it was diluted with buffer A containing 0 1 M Ca2+ so as
to clot in 70-80 s a mixture ot 120 1tl of plasma, 30 pl of thromboplastin
and 30 pl of buffer A.
Methods
Heparin Fractionation
From one of the enoxaparin batches (88.145.02) eight fractions with
narrow molecular weight distribution were obtained by gel permeation
chromatography on ACA 202 and ACA 54 (Tables 1 and 2). The mobile
phase was 0 33 M NaCl. The average molecular weight of the fractions
obtained (N6 to N36) was determined by High Performance Size
Exclusion Chromatography (HPSEC) coupled with Laser Light Scatter-
ing. In addition, we estimate the average number of disaccharidic units
per chain by 13C NMR analysis Q ). The narrow elution profiles and the
ratio of weight average to number average molecular weights of close to
unity indicated a limited degree of polydispersity. HPSEC was performed
on a system that consists of a Gilson 302 pump, an RID 6 A differential
refractometer (Shimadzu) and an SF UV detector (Kratos). Aqueous
solutions of enoxaparin at 10 mg/ml were analysed on a two-column
system (TSK G 3000 SW-30 x 0.75 cm and Lichrosorb 100 diol 25 x
0.75 cm). The mobile phase (0.3 M phosphate buffer, pH 7) was used at
flow rate 0.75 ml/min. Due to the narrow distribution of the fractions.
they were used to calibrate the chromatographic system used subsequently
for the determination of the MW of enoxaparin. This was determined by
HPSEC coupled with refractometry.
Fluorescence Measurements
The molar concentrations of the HAM in each isolated fraction were
determined by a stoichiometric titration of AT III (0.5 pM) in buffer (Tiis
HCI 50 mM, NaCl 0.1 M, pH 7.5) as described in ref. (25). Briefly, the
binding of a heparin fraction to Antithrombin III results in an increase of
the tryptophan fluorescence of the protein (excitation at 285 nm, emission
at 345 nm; ref. 26). The fluorescence increase is calculated as (F'-F")/
F^-Fo, where F is the fluorescence intensity of the sample containing
heparin, fl" that of the control solution without heparin, and F- is the
fluorescence obtained at the saturation concentrations. The fluorescence
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Fig.2 High affinity heparin fraction as a function of molecular weight.
The percentage of HAM was obtained from the fluorometric titration
of AT III (Table 2), and the molecular weight from the data shown in
Thble 1
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Table I Properties of the enoxaparin fractions
HPLC: data from high performance liquid chromatography; NMR: data
from nuclear magnetic resonance; MW: weight average molecular weight;
WIN'. ratio of weight and number average molecular weight; N: number of
monosaccharide units. S/Cx gives the ratio of sulfate/carboxyl. N.", gives
the number of monosaccharides of the main component of the fraction
assessed from the experimental data, and knowing it to be an even integral
number. ACL.ld% gives the percentage of material with a MW
> 5 4 k D a .
Table 2 AT III binding material of the enoxaparin fiactions
first order rate constants by calculating the increase of ft1 per pg of
heparin. k2 appeared not to be dependent on the amount of heparin
added.
Thrombin Generation in Plasma
240 ytl of defibrinated plasma is supplemented with 60 pl of buffer A,
containing heparin at the desired concentration and incubated for 5 min at
37" C. Ar zero time, thrombin generation is started by the addition of
60 pl of a solution containing 100 mM of CaCl2, and a trigger of
coagulation. For the extrinsic system this is human brain thromboplastin,
as described in the previous section For the intrinsic system, 1 pM
phospholipid and 0.025 mg kaolin (final concentration). At intervals, a
10 pl aliquot of the mixture is sampled into a disposable plastic cuvette
containing buffer and chromogenic substrate, as described above. The
optical density is mcasured at 405 nm. The amidolytic activities in the
plasma samples are calculated from the O.D., and expressed as the
equivalent concentration of thrombin (in nM), according to a reference
curve obtained with active site titrated purified human cr-thrombin. From
the curves of amidolytic activity the thrombin concentrations were
obtained as previously described (8). Of each heparin species a series of
concentrations was tcsted so as to find that one (IC25) that inhibits the
peak of generated thrombin by 25%. The unconventional IC25 was
choosen rather than IC50 in order to allow comparison with the IC25 of
prothrombinase (see results section).
Prothrombinase Activity in Plasma
The generation of prothrombinase activity is calculated from the
amidolytic activity currr'e thrombin generation as described previously (8).
Briefly, the observed amidolytic activity is the sum of thrombin activity
and the partial activity of o2M-thrombin complex. The rate of thrombin
generation at any moment is the sum of two processes: a) the conversion
of prothrombin into thrombin by prothrombinase and b) the decay of
thrombin by the action of plasma protease inhibitors. The rate of
inhibition of thrombin at any time can be calculated from the concentra-
tion of thrombin at that moment and the pseudo-first oder rate constant of
thrombin inhibition by antithrombin III (t1) and n2-macroglobulin (ft2).
Heporin Concentrollon, pg / ml
Fig. 3 The decay constant of endogenous thrombin in normal plasma as a
function of the heparin concentration. The specific anti-thrombin
activities of the heparins (see text) are obtained from the slopes of these
lines Upper frame: Open symbols: Enoxaparin (three batches);
O: N14; A:  N20. Lower f rame: V:  N28; O: N32; V:  N36
Heparin HPLC NMR N.., ACLM
%MW wlN S/Cx
N6
N8
N10
N14
N20
N28
N32
N36
1,800
2,400
2,900
4,200
6,200
8,600
9,800
11,000
1.08
r.02
02
01
01
01
1.03
1.05
6.2
8 0
9.1
t4.0
20.7
28.r
32.7
36.6
7  2 . 4
9  2 4
10 8  2 .2
t4 5 2.2
20.8 2.0
6  < 3
8  < 3
1 0 3
14 10
20 67
2 8  > 9 5
3 2  > 9 5
3 6  > 9 5
Heparin IPC
(pg/ml)
BS HAM
(rrM/-g) (.%)
N6
N8
N10
N14
N20
N28
N32
N36
enox
1.14
36
31
21.
10
9
8
10
16
8.8
27
48
50
55
62
52
37
1
6
9
20
3t)
50
61.
57
I4
IPC: Concentration of heparin at the inflection point, necessary to
saturate the 0.5 pM of AT III present in the experiment. BS: Binding site
content of heparin calculated (pM/-g). HAM: The percentage of
antithrombin III high affinity molecules calculated from the binding site
content and the molecular weight
Thble 3 Soecific anti-thrombin activities
Heparin Total HAM ACLM ACLM*
Enoxaparin
N6
N8
N10
N14
N20
N28
N32
N36
1.05
0
0
0
0.07
3.30
6.14
6.69
9.62
7 .5
0
0
0
0.35
11
12.3
10.8
16.9
12.3
0
0
0
3 .5
1 6 3
72.3
10.8
1,6.9
2.63
1.34
1.10
1.35
*) The activities are expressed in min t (pg/-t)-t except for the last
column that is in min 1 nM 1
of thrombin generated in plasma is calculated by fitting the data to
C , :  Cn  +  Coe  t ' t ,
where C, is the thrombin activity at time /, Cp is the steady endJevel
activity, Co + CR is the amidolytic activity at the time of SBTI addition.
The observed decay constant is thc sum of two constants, k : kr 1- kzl
k1 is the AI Ill-dependent decay constant of inhibition of thrombin, k2 is
the decay constant of inhibition of thrombin by o2-macroglobulin (o2-M).
The ratio of klto k2 is determined as the ratio of the amounts of thrombin
complexed with AT III and o2-M as described previously (8). From their
sum and their ratio the constants are calculated k1 in all instances is
lineary dependent upon the heparin concentration, so the second order
rate constants of thrombin inhibition could be obtained from the pseudo-
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The rate of prothrombin activation (prothrombinase activity) then can be
calculated from the observed rate of generation of amidolytic activity and
the rate of  thrombin inhib i t ion.
Results
Physicochemical Properties and AT III Affinity of the Fractions
Table 1 summarises the data obtained from the physicochemi-
cal characterisation of the fractions. The ratio of near unity of the
weight average to the number average molecular weight demon-
straies the nuiro* distribution of the MW of these fractions' Also
in Thble 1 one finds the chainlength as calculated from the HPLC
data on basis of a mean MW of 300 per monosaccharide unit, as
well as the chainlength obtained from the 13C NMR data' From
from HPLC profiles.
The titration of AT III with the heparins permitted to calculate
the active concentration of heparin at the equivalence point'
heparin molecule.
The Specific Antithrombin Activity
The effect of increasing concentrations of the heparins on the
pseudo-first order decay constant of endogenous thrombin was
determined. For each of the preparations the constant increased
Thrombin
linearly with the concentration of the heparin (Fig.3). From the
slope of these lines we determined the specific activity of the
heparins (Table 3). We define the specific acitivty of a heparin as
the increase of the decay constant of thrombin in plasma per pgl
ml of heparin. (It can also be expressed per nanomole in those
preparations of well defined molecular weight. A specific anti-
iactor Xa activity can be defined analogously). Reasoning that the
activity is caused by molecules with a high affinity to AT III and
above the critical chainlength of 18 monosaccharide units,
we calculated the specific activities of both the HAM and the
ACLM in the fractions. The specific activity of enoxaparin is
1.050 min-l pg-1 ml (mean of three batches), which is close to the
value of 1.110 min-1 pg-r ml) calculated from previous data (17)'
This amounts to 7.500 min 1 per pglml of HAM and 3I'250 per
pglml of ACLM.
The Overall Inhibition of the Thrombin Peak
The inhibitory activity of the heparin on the formation of free
thrombin in clotting plasma is an over-all effect that can be due to
both an increased decay of thrombin and an decreased prothrom-
bin conversion. We can calculate (see methods section and ref' 8)
what part of the over-all inhibition is to be attributed to inhibition
of prothrombin conversion and what part to the acceleration of
thrombin decay. This calculation is based on the observed
thrombin activities and requires a minimum of - 20% of residual
thrombin activity to maintain the required accuracy. Half total
inhibition of prothrombin conversion often occurs at > 80%
inhibition of the thrombin peak. We therefore determined the
concentration of heparin necessary to obtain 25'/" of the pro-
thrombinase activity, and compared it to the heparin concentra-
tion that causes 257o inhibition of the thrombin peak (IC25' Table
4). This was done both in the extrinsic- and the intrinsic system
(Fig. a). The results were again expressed in terms of HAM' We
did not present the results in t..rms of ACLM, since prothrombin-
ase inhibition is not necessarily confined to heparin molecules
longer than the critical chainlength
Prothrombinose
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Fig.4 The inhibition of thrombin and prothrombinase as a function of heparin concentration. For experimental details see methods section. Upper
frimes: extrinsic system; lower frames: intrinsic system. O: N6; O: N8; A: N10; A: N14; n: N20; O: N28; V: N32l V: N36
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Heparin Thrombin
Thble 4 Concentrations that cause 25% inhibition
-t:
HAM ACLM
Prothombinase
AII HAMAll
A1) Weight basis (ng/ml), extrinsic system E
o
. E s
)
N20 200 60
N28 70 35
N32 80 50
N36 90 51
Enoxaparin
N6
N8
N10
N14
N6
N8
N10
N14
N20
N28
N32
N36
450 63
15,800 158
4,500 270
3,400 306
2,200 440
15,800 158
4,400 264
3,800 342
1,600 320
250 75
50 25
80 50
60 34
750 105
15,800 158
4,500 270
3,400 306
2,600 520
170 85
270 130
340 I94
750 105
15,800 1s8
4,400 264
3,800 342
1,600 320
8,780
1,875
t,r70
619
18
27
27
8,780
1,830
1,310
380
(26)
52
40
35
50
51
A2) Weight basis (nglml), intrinsic system
Enoxaparin 550 77 (32)
E
o
F a
q
o)-)L50
25
50
34
75 37
160 99
130 74
8
16
10
82) Molar basis (nM), intrinsic system
N6
N8
N10
N14
N20
N28
8,780 88
1,830 110
11310 118
380 76
40 12
6 3
It was systematically observed that heparin does not cause a
prolongation of the lag-phase in the extrinsic system but all
fractions studied prolong the lag-phase in the intrinsic pathway
(Fig. s).
Discussion
Heparins need a chainlength of 18 saccharides or more in order
to catalyse thrombin breakdown but the anti-factor Xa activity
requires only a pentasaccharide sequence (13). It is often sug-
gested that the smaller a heparin is, the more it exhibits a specific
anti-factor Xa activity (2-6). In the usually highly disperse
LMWH preparations this can mean either of two things. First, is it
possible that in heparin preparations with low mean molecular
weight, the proportion of molecules with uniquely anti-factor Xa
properties is high. Second there might be a gradual change of
properties with the chainlength i. e. the heparins become propor-
tionally more efficient thrombin inhibitors with increasing chain-
length. There are no quantitative data available from the litera-
ture on the variation of the catalytic activity with the chainlength
under circumstances comparable to those where heparins exert
their therapeutic action, i. e. in plasma in the presence of Ca2+
ions, although it has been well documented that the effect of Ca2*
is important (2729).
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Flg.5 The lag-phase of intrinsic thrombin generation as a function of
heparin concentration. Upper frame: O: Fnoxaparin; O: N6; A: N8;
A: N10; ! :  N14. Lower f rame: I :  N20; V:  N28; V:  N32; O: N36
In this study, it was our aim to determine the effect of heparin
chainlength on thrombin breakdown and prothrombin conversion
under circumstances comparable to those in which heparins
exhibit their therapeutic action, i. e. in clotting plasma. To this
end we prepared a series of subfractions of the LMWH enoxapa-
rin. These fractions appear to have a narrow molecular weight
distribution, the ratio of weight average and number average
molecular weight is near unity and the chainlength obtained by
dividing the molecular weight through the mean molecular weight
of one monosaccharide unit (300) gives a figure near to the
number obtained from NMR measurements. We therefore think
that the fractions are reasonably homogeneous with respect to
their chainlength.
They remain heterogeneous as to chemical composition. This
already follows from the observation that the relative amount of
material with high affinity to AI III decreases with decreasing
molecular weight. This is a logical consequence of the LMWH
preparations being obtained by random fragmentation of conven-
tional heparin. With an increasing of cleavages the mean molecu-
lar weight of the resulting product drops, but also the probability
increases that the high affinity pentasaccharide region is severed
so that the remaining molecule looses its HAM character. This
automatically implies that the MW distribution of the HAM
fraction within a LMWH cannot be the same as that of the total
fraction. It must be shifted to the higher MW ranges. This again
implies that it must be possible that isolation of a narrow zone of
higher MW material from a LMWH will cause a relative gain of
high affinity material, which explains that in some fractions the
HAM content can be higher than in the original material.
The Specffic Antithrombin Activity
To judge the effect of the molecular size on the activity, one
should express the activities on basis of the amount of active
material, i. e. in terms of high affinity material (HAM) and, when
anti-thrombin activities are concerned in terms of hieh affinitv
0.5
81) Molar basis (nM), extrinsic system
N6 8,780 88
N8
N10
N14
N20
N28
N32
N36
t2
7
4
5
7.6
8
2 7
5 . 1
2-7
8 5
5 3
N32
N36
t,875 1,12
t,170 106
524 123
32 10
8 4
8 5
8 5
88
t72
106
123
9
13
76
88
110
118
76
4
10
6
material above the critical chainlength of 18 monosaccharide units
(ACLM). In another study (30) we compared the specific
activities of an ultralow-, low-, and middle molecular weisht
fractions of another LMWH (CY2l6) and the isolated high
affinity material obtained from them. We could show that the
specific activity of the isolated high affinity material is indistin-
guishable from that of the original materials when corrected for
the non-affine material. We define the specific anti-thrombin
activity as the increase of the pseudo-first order decay constant of
endogenous thrombin in normal plasma brought about by 1 pg/ml
of heparin. (Alternatively, with heparin preparations of well
defined molecular weight, one can express the specific activity per
nanomole.) If the specific activity were constant with unit weight
this would mean that the catalytic activity of a heparin molecule
increases proportionally with its length, if it would be constant per
molar unit this would indicate that being longer than 18 monosac-
charide units is a necessary and sufficient condition for a heparin
molecule to express full antithrombin activity.
Table 3 gives the specific activities found. It is confirmed that
only the fractions with a chainlength > 18 saccharide units possess
anti-thrombin activity. The. heparins without significant anti-
thrombin activity (fractions N6-N14) we call P-type heparins, the
others S-type heparins (16). Within the S-type group, no signifi-
cant systematic variation of the specific activity can be observed
with the chainlength, neither when expressed on a weight- or on a
molar basis. The data do not allow to distinguish between these
two possibilities. A larger series of heparins with well defined
chainlengths between 20 and 40 monosaccharide units will have to
be available to settle that question.
The Inhibition of Prothrombin Conversion
The inhibition of extrinsic prothrombinase is a consequence of
the inactivation of factor Xa. The inhibition of the intrinsic
prothrombinase is a combined effect of factor Xa inactivation and
inhibition of factor X activation (see below). The IC25 values for
extrinsic prothrombinase inhibition, even when corrected for the
non-affine material present, are lower for the S type heparins than
for the P type materials. This is already clear when expressed on a
weight basis and it is even more evident when they are expressed
in molar units (Table 4). This shows that in plasma, in the
presence of Ca2+ ions, the medium molecular weight heparin
species are more potent inhibitors of factor Xa than the ultra-low
species are. This was also observed in a purified system (31,32).
Within the S or the P group no systematic shift of the activity with
the molecular weight can be observed. It is rather as if the
difference that brings about the anti-thrombin activity also
increases the antiprothrombinase (i. e. anti-factor Xa) activity.
Table 4 suggests that the effect of the higher molecular weight
species (> N20) in enoxaparin on intrinsic prothrombinase activ-
ity is more important than on the extrinsic one. This can be
explained by their antithrombin activity, on the thrombin depen-
dent feedback activation of factor VIII (12, 16,34:36). This not
only causes a prolongation of the lag-phase (Fig.5) but also
prevents factor IXa from being protected by factor VIIIa, so that
it is inactivated by AT Ill-heparin and less prothombinase is
formed. This mechanism has been shown to be operative with
unfractionated heparin (37).
The Overall Inhibition of the Thrombin Peak
The inhibition of the thrombin peak is the combined effect of
inhibition of prothrombin conversion and enhancement of throm-
bin breakdown. Within the P group IC25 for thrombin inhibition
is equal to that of prothrombinase inhibition, which is a logical
consequence of their acting through inhibition of prothrombin
conversion only. The value scatters around 100 nM (Table 4).
In the S group the concentration necessary to inhibit for 25o/o
the thrombin peak is 2 to 4 times lower than that required to
obtain a similar inhibition of prothrombinase. This indicates that
the main effect of the S-type heparin is on thrombin breakdown
and that their anti-factor Xa activity, although definitely present,
does not contribute much to the overall inhibition of the thrombin
peak. Comparison of the IC25 values of the original enoxaparin
and the fractions N6-N36 shows that the molecular soecies
<6,000 are hardly active in thrombin inhibition. Because of the
limited amount of material with MW >9,000 in enoxaparin, we
must conclude that the main active species must be thought to
have a chainlength of between 20 and 30 saccharide units.
Our findings pertain to the question of the importance for a
LMWH to have an anti-factor Xa activity. Ever since Yn (38)
suggested that, to obtain adequate anticoagulation, inhibition of
factor Xa might be a more efficient means than inhibiting
thrombin, this idea has persisted in the literature (e.g. ref.7). In
fact, because factor Xa is only one of the three components of the
prothrombin activating enzyme (39, 40), and because, under the
conditions in clotting plasma it is not the rate limiting component
(16), inhibition of factor Xa is an inefficient way of inhibiting
thrombin generation (12, 14,40).
It follows from our results that a considerable amount of the
activity of enoxaparin, like that of unfractionated heparin, is due
to its anti-thrombin properties. It is likely to be irrelevant for the
antithrombotic activity whether the generation of thrombin is
inhibited or its inactivation enhanced. This seems to be in
accordance with results obtained in experimental thrombosis in
animals (1 and references therein). The fact that both oral
anticoagulation and heparin treatment are effective antithrombo-
tic strategies, although acting by completely different mechan-
isms, points in that direction. Probably the clinical efficacy of a
LMWH is determined by a compromise between inhibitory
properties, that become more pronounced with higher MW, and
pharmacokinetical proterties such as half-life time and bioavaila-
bility, that are more favourable in smaller molecules.
Acknowledgements
We thank the "Broeders van de Beijaard" for their gcnerous donations
of normal plasma and M Vuilhorgne for carrying out the t3C NMR
analyses. The fruitful discussions with Theo Lindhout are gratefully
acknowledged.
REFERENCES
1. Chesebro JH, Zoldheyi P, Badimon L, Fuster V. Role of thrombin in
arterial thrombogenesis: Implication for therapy. Thromb Haemostas
l99l:66: I-4.
2. Thunberg L, Lindahl U, Tengblad A, Laurent TC, Jackson CM On
the molccular-weight-dependcnce of thc anticoagulant activity of
heparin Biochem J 7979; l8l:241-3
3 Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, S6den-
strom G. Molccular weight dependency of the heparin potentiated
inhibition of thrombin and activated factor X Effect of heoarin
neutralization in plasma. Thromb Res 1979; 15: 531-41.
4. Lane DA, Denton J, Flynn AM, Thunbcrg L, Lindahl U. Anticoagu-
lant activities of heparin oligosaccharides and their neutralization by
platelet factor 4 Biochem J 1984;2I8:725-32
5. Barrowcliffe TW Mcrton RE, Havercroft SJ, Thunberg L, Lindahl
U, Thomas DP Anticoagulant activities of heparin oligosaccharides.
Thromb Res 1984; 34:125-33.
6. Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U
Effects of heparin oligosaccharides with high affinity tbr antithrom-
bin III in experimental venous thrombosis Thromb Haemostas 1982;
47:244-8
s6I
7. Bratt G, Ttjrnebohm E, Lockner D, Bergstrrim K' A human
pharmacological study comparing conventional heparin and a low
molecular heparin fragment. Thromb Haemostas 1985; 53: 208-17'
8. Hemker HC, Willems GM, B6guin S. A computer assisted method to
obtain the prothrombin activation velocity in whole plasma indepen-
dent of thrombin decay processes. Thromb Haemostas 1986; 56: 9-1'7 '
9. Jesty J. Analysis of the generation and inhibition of activated
coagulation factor X in pure systems and in human plasma J Biol
Chem 19861 261': 8695J02.
10. Jesty J. The kinetics of inhibition of o-thrombin in human plasma' J
Biol Chem 1986; 261: 10313-8.
11. Bendetowicz AY Bara L, Samama M. The inhibition of intrinsic
prothrombinase and its generation by heparin and four derivatives in
prothrombin poor plasma. Thromb Res 1989; 58:445-54'
12. Edguin S, Lindhout ! Hemker HC. The mode of action of heparin in
1989;61:  397-401'-
15. Walenga JM, Bara L, Petitou M, Fareed J, Samama M, Choay J' The
inhibition of the generation of thrombin and the antithrombotic effect
of a pentasaccharide with sole anti-factor Xa activity' Thromb Res
1988 ;51 :  23 -33 .
16. Hemker HC. The mode of action of heparin in plasma Xlth Congress
Thrombosis Haemostasis, Brussels Verctraete M, Vermylen J, Lij-
nen HR, Arnout J (eds). Leuven University Press, Leuven 1987; pp
l'7-36
17. B6guin S, Mardiguian J, Lindhout t Hemker HC' The mode of
action of low molecular weight heparin preparation (PK 10169) and
two of its major components of thrombin generation in plasma'
Thromb Haemostas 1989; 61: 30-4.
18. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method'
Increased sensitivity by adding purified antithrombin III' Thromb Res
1977:'10: 399-470.
19. Bara L. Combe-Thmzali S, Conard J, Horellou MH, Samama M'
Modifications biologiques induites par trois h6parines de bas poids
mol6culaire: PK 10169, Kabr2765 etCY 21'6, compar6es h l'h6parine
non fractionn6e, inject6es par voie sous-coutan6e chez le volontaire
sain en chirurgie glndrale et chezle sujet A96 en mddecine J Mal Vasc
1987:. 12: 78-84.
20.Tha1er E, Schmer G. A simple two-step isolation procedure for
human and bovine antithrombin IUIII (heparin cofactor): a comparl-
son of two methods. Br J Haematol 1975;3L:233-43'
21. Miller-Andersson M, Borg H, Andersson LO. Purification of anti-
thrombin III by affinity chromatography' Thromb Res 1974; 5:
439-52.
22. Smith RL. Titration of activated bovine factor X. J Biol Chem 1973;
248:2418-23.
23. Owren PA, Aas K. The control of dicumarol therapy and the
quantitative determination of prothrombin and proconvertin' Scand J
Clin Lab Invest 1951; 3: 201-18.
24. Casr B, Oreste R Torri G, Zopetti G, Choay J, Lormeau J-C, Petitou
M. The structure of heparin oligosaccharide fragments with high anti-
(iactor Xa) activity containing the minimal antithrombin-Ill binding
sequence. Biochem J 1981; 197: 599-609-
25. Schoen P, Wielders S, Petitou M, Lindhout T The effect of sulfation
on the anticoagulant and antithrombin Ill-binding properties of a
heparin fraction with low affinity for antithrombin III' Thromb Res
1990;57: 41523.
26. Nordenman B, Danielsson A, Bj6rk I: The binding of low affinity and
high affinity heparin to antithrombin. Fluorescence Studies Eur J
Biochem 1978;90:  1-6.
27. O'Neall-Speight M, Griffith MJ. Calcium inhibits the heparin-cata-
lyzed antithrombin Ill/thrombin reaction by decreasing the apparent
binding afinity of heparin for thrombin. Arch Biochem Biophys 1983;
225:958-63.
28. Barrowcliffe TW, Shirle Le Y. The effect of calcium chloride on anti-
Xa activity of heparin and its molecular weight fractions' Thromb
Haemostas 1989: 62: 95-954
29. Schoen P, Lindhout R Franssen J, Hemker HC. Low molecular
weight heparin-catalyzed inactivation of factor Xa and thrombin by
antiihrombin IIL Effect of platelet factor 4. Thromb Haemostas 1991;
66: 435-4I
30. B6guin S, Wielders S, Lormeau JC, Hemker HC. The mode of action
of CY2l6 and CY222 in plasma. Thromb Haemostas 7992;67:33-47'
31. Ellis V, Scully ME Kakkar W. The relative moleculat mass
dependence of the anti-factor Xa properties of heparin. Biochem J
1986;238: 329-33.
32. Barrowcliffe TW, Havercroft SJ, Kemball-Cook G, Lindhal U' The
effect of Ca+2, phospholipid and factor V on the anti(-factor Xa)
activity of heparin and its high-affinity oligosaccharides' Biochem J
I98: 243: 3I-7.
33 Danielsson A, Raub E, Lindahl U, Bjork I. Role of ternary
complexes, in which heparin binds both antithrombin and proteinase,
in tle accelaration of the reactions between antithrombin and
thrombin or factor Xa. J Biol Chem 1986; 267: 15467-'73.
34 Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman
MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent
positive feedback reactions is critical to the expression of the
anticoagulant effect of heparin. Biochem J 1987;243:579-88'
35. Ofosu FA, Smith LM, Anvari N, Blajchman MA An approach to
assigning in vitro potency to unfractionated heparin and low molecu-
lar weight heparins based on the inhibition of prothrombin activation
and caialysis of thrombin inhibition. Thromb Haemostas 1988; 60:
193-8.
36. Pieters J. Lindhout T Hemker HC' In situ generated thrombin is the
only enzyme that effectively activates factor VIII and factor V in
thromboplastin activated plasma. Blood 1989; 
'74: 1021'-4'
37. B6guin S, Dol R Hemker HC. Factor IXa inhibition contributes to
the heparin effect. Thromb Haemostas 199I;66: 3O6-9
38. Yin ET Wessler S, Stoll PJ' Biological properties of the naturally
occuring inhibitor to activated factor X. J Biol Chem I97l; 246:
3706-rr.
39. Hemker HC, Esnouf MP, Hemker PW, Swart ACW, Macfarlane RG'
Formation of prothrombin converting activity. Nature 1968; 215:
246-5r.
40. Rosing J, Thns G, Govers-Riemslag JWP, Zwaal RAF, Hemker HC
The role of phospholipid and factor Va in the prothrombinase
complex. J Biol Chem 1980;249: 7798-807 '
41. Pieters J, Lindhout T The limited importance of factor Xa inhibition
to the anticoagulant property of heparin in thromboplastin-activated
plasma. Blood 1988; 72:2048-52
Received June 4, 1991 Accepted after revision December I'7,1991
562
